Figure 1.
Figure 1. Evolution of %V617F during treatment with peg–IFN-α–2a. (A) Evolution of %V617F in all patients. (B) Mean decrease of %V617F at 6 and 12 months.

Evolution of %V617F during treatment with peg–IFN-α–2a. (A) Evolution of %V617F in all patients. (B) Mean decrease of %V617F at 6 and 12 months.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal